Company Overview

argenx SE is a global immunology-focused biotechnology company dedicated to developing antibody-based therapies for the treatment of severe autoimmune diseases and certain cancers. The company operates primarily within the biopharmaceutical and biotechnology industries, with a core emphasis on translating immunology research into targeted, first-in-class medicines. Its business is centered on the discovery, development, and commercialization of proprietary antibody therapeutics designed to selectively modulate the immune system.

The company’s primary revenue driver is its lead product Vyvgart (efgartigimod), an FcRn antagonist approved for the treatment of generalized myasthenia gravis and additional indications, generating the majority of commercial revenue. argenx serves specialist physicians, hospitals, and patients in neurology and immunology markets, particularly those addressing rare and severe autoimmune conditions. Founded in 2008 and originally spun out of academic antibody research, argenx has evolved from a clinical-stage biotechnology firm into a fully integrated commercial organization with global operations and multiple late-stage development programs.

Business Operations

argenx operates through an integrated model that includes research and development, clinical development, and commercial operations, with revenue primarily derived from product sales and strategic collaborations. The company’s key business segments are centered on immunology therapeutics and antibody discovery platforms, with efgartigimod serving as the cornerstone asset across multiple indications and formulations, including intravenous and subcutaneous delivery.

Operations span both domestic and international markets, with commercialization activities in North America, Europe, and parts of Asia. argenx controls proprietary antibody engineering and FcRn biology expertise, supported by internal R&D capabilities and external manufacturing partners. The company maintains strategic partnerships for co-development, regional commercialization, and manufacturing, and operates through wholly owned subsidiaries that manage local regulatory approvals, sales, and distribution.

Strategic Position & Investments

argenx’s strategic direction is focused on expanding its immunology franchise by broadening the label and geographic reach of Vyvgart, while advancing a pipeline of novel antibody candidates targeting autoimmune and inflammatory diseases. Growth initiatives include late-stage clinical trials in additional neurology and immunology indications, lifecycle management through new formulations, and investments in next-generation antibody technologies.

The company has made targeted acquisitions and licensing deals to strengthen its discovery capabilities and pipeline, while also investing heavily in internal R&D infrastructure. Notable subsidiaries support clinical development and commercialization activities across key markets. argenx is actively involved in emerging areas of immunology, including precision modulation of pathogenic antibodies, positioning the company as a leader in FcRn-targeted therapies.

Geographic Footprint

argenx is headquartered in Amsterdam, the Netherlands, and maintains a significant operational presence in the United States, which represents its largest commercial market. Additional key regions include Europe and Asia-Pacific, where the company conducts clinical trials, regulatory activities, and commercial operations.

The company’s global footprint includes offices and subsidiaries across multiple continents, enabling international clinical development and product launches. argenx’s geographic diversification supports regulatory approvals, physician engagement, and patient access in both established and emerging biopharmaceutical markets, while also facilitating global research collaborations.

Leadership & Governance

argenx was co-founded by Tim Van Hauwermeiren, who continues to shape the company’s long-term strategy and culture. The leadership team emphasizes a patient-centric philosophy, scientific rigor, and disciplined capital allocation, with a strategic vision centered on building a sustainable, global immunology company.

Key executives include:

• Tim Van Hauwermeiren – Chief Executive Officer
• David E. Luyten – Chief Medical Officer
• Bernard de Vos – Chief Financial Officer
• Nicolas Leupin – Chief Operating Officer
• Elisabeth Björk – Chief Scientific Officer

The company is governed by an experienced board of directors with backgrounds in biotechnology, pharmaceuticals, and global business leadership, supporting oversight, regulatory compliance, and long-term value creation.